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ABSTRACT 
Background: Data on the effectiveness of 1 dose of HPV vaccine are lacking, particularly in 
population-based settings.  Data from a national HPV immunisation catch-up programme of 
14-18 year old girls were used to assess the effectiveness of < 3 doses of the bivalent vaccine 
on vaccine-type and cross reactive-type HPV infection. 
Methods:  Cervical samples from women attending for their first cervical smear, which had 
been genotyped for HPV as part of a longitudinal HPV surveillance programme were linked 
to immunisation records to establish the number of vaccine doses (0,1,2,3) administered.   
Vaccine effectiveness (VE) adjusted for deprivation and age at first dose, was assessed for 
prevalent  HPV 16/18 and HPV 31/33/45 infection.  
Results: VE for prevalent HPV 16/18 infection associated with 1, 2 and 3 doses was 48.2% 
(95% CI 16.8-68.9), 54.8% (95% CI 30.7-70.8) and 72.8% (95% CI 62.8-80.3). Equivalent VE for 
prevalent HPV 31/33/45 infection was -1.62% (95% CI -85.1 – 45.3), 48.3 % (95% CI 7.6 -71.8) 
and 55.2 % (95% CI 32.6-70.2). 
Conclusion: Consistent with recent aggregated trial data, we demonstrate the potential 
effectiveness of even one dose of HPV vaccine on vaccine type infection. Given that these 
women were immunised as part of a catch-up campaign, the VE observed in this study is likely 
to be an underestimate of what will occur in girls vaccinated at younger ages. Further 
population-based studies which look at the clinical efficacy of one dose schedules are 
warranted.  
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INTRODUCTION 
There is now overwhelming global evidence to demonstrate that the licensed bivalent and 
quadrivalent Human Papillomavirus (HPV) vaccines are highly efficacious for the prevention 
of HPV infection and associated disease when administered as a 3 dose schedule. However, 
as described more recently, a 2  dose schedule with an extended interval between doses  1 
and 2 has also been demonstrated to be efficacious (Drolet et al, 2015, Lowy et al,  2015). The 
move to a 2 dose schedule offers clear cost and logistic advantages. However, the data on the 
efficacy of 1 dose is relatively sparse. Given that the majority of countries where HPV vaccine 
is needed most, view national immunisation programmes as cost-prohibitive, the case and 
potential effectiveness for 1 dose schedules requires further investigation.  In a recent article 
by Kreimer et al (2015) which used combined data from the Costa Rica Vaccine Trial (CVT) and 
PATRICIA, the authors showed that 4 years after women aged 15-25 were vaccinated  with 
the bivalent vaccine, one dose (and two doses administered at 0 and 1 months) provided 
significant  protection against HPV16/18 infection.  
 In Scotland, females aged 12-13 have received HPV vaccine at school since 2008 with an initial 
3 year “catch-up” for females aged 14-17 years and 364 days.  Since 2011, catch-up females 
have entered the Scottish cervical screening programme (SCSP), which first invites women 
from the age of 20. Longitudinal surveillance of vaccine impact on HPV infection and disease 
is possible as vaccine status - including number of doses - can be linked to a cervical screening 
record and a significant impact of 3 doses of the bivalent vaccine  on both HPV infection and 
associated disease has been observed (Kavanagh et al 2013 & 14, Pollock et al 2014).    Our 
aim in the present analysis, by supplementing our standard surveillance with additional 
sampling of those vaccinated with 1 and 2 doses, was to assess vaccine effectiveness (VE) on 
prevalent HPV infection in women who received < 3 doses of the bivalent vaccine, thereby 
complementing the trial-based work of Kreimer and colleagues with a population-based 
analysis. 
 
MATERIALS AND METHODS 
Overview of Epidemiology and Surveillance Programme and derivation of sample set 
The overarching structure of the HPV Immunisation programme in Scotland and the 
associated Scottish epidemiology and surveillance programme has been described elsewhere 
(Kavanagh et al 2013, Kavanagh et al 2014).  Briefly, one aspect of the surveillance programme 
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involves monitoring of HPV infection in women attending for first smear. Since 2009 a yearly 
tranche of ~2000 residual cervical cytology samples from women (attending for first smear) 
has been collated from all NHS cytopathology laboratories that serve the SCSP. Collated 
samples were subject to HPV genotyping  by the Optiplex HPV genotyping assay (Diamex, 
Heidelberg, Germany) which can delineate 24 HPV types including all established high-risk 
types.  All residual samples are stored in the Scottish HPV Archive, a national repository and 
“collection of collections” of cervical samples for use in research 
http://www.shine.mvm.ed.ac.uk/archive.shtml.  Linkage of the sample through a cervical 
screening record to vaccination status, including number of doses was made through use of a 
unique identifier.  The present analysis was designed specifically to report on the impact of < 
3 doses of vaccine on prevalent HPV infection and represents one of several pieces of work 
performed in Scotland designed to look at the impact of vaccine on various outcomes 
including -  infection (Kavanagh et al 2014, Bhatia et al 2015), histological abnormalities 
(Pollock et al 2014) cytology performance (Palmer et al 2016a) and) screening uptake (Palmer 
et al 2016b).  
 
Detail of Sample set used for <3 dose analysis 
Analysis was based on women who had received vaccine as part of a catch-up programme 
that ran for girls up to age 17 years and 364 days (women born in 1988-1993).  As described 
above, for standard immunisation surveillance in Scotland, ~2000 samples are collated and 
from all laboratories that serve the Scottish Cervical Screening Programme (proportionate to 
their remit) and stored, of which ~ 1000  geographically representative samples are 
genotyped. Table 1 shows overall demographics of the population tested for the present 
analysis stratified by vaccine status. To augment the number of samples from women who 
received < 3 doses, all additional stored samples (n=234) associated with < 3 doses collected 
from women born in 1988-1993 were also tested.  Thus, the final analysis incorporated a total 
of 300 samples from women who had received 2 doses, generally administered at 0 and 1 
month(s), whereas 177 had received  1 dose only. This compared to 1853 that had 3 doses of 
vaccine over the same time frame. As the unvaccinated group necessarily incorporated older 
birth cohorts,  adjustments for birth cohort and age at receipt of vaccine were made (see 
below).  
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Analysis  - vaccine effectiveness 
To estimate vaccine effectiveness, the adjusted odds ratio (OR) of prevalent infection with 
both HPV 16/18 and HPV 31/33/45 (in aggregate) for 1, 2, and 3 doses of vaccination was 
estimated using logistic regression by comparing to the unvaccinated group and VE calculated 
as 100*(1-OR). The odds of HPV infection was adjusted for deprivation through use of the 
Scottish Index of Multiple Deprivation Score (SIMD), birth cohort (to account for any potential 
temporal changes in HPV prevalence) and age at receipt of first dose for those vaccinated, as 
those who were vaccinated at older ages  - and therefore outside the schools based 
programme – were more likely to have received < 3 doses.  VE for women who received 3 
doses over the same time frame is presented for context and comparison. 
 
RESULTS 
HPV prevalence in women with 0, 1,2 and 3 doses of vaccine – unadjusted analysis 
Table 2 shows the prevalence of HPV 16/18 and HPV 31/33/45 stratified according to number 
of vaccine doses.  Prevalence of HPV 16/18 was highest in women who received 0 doses of 
vaccine (29.3%) and lowest in those who received 3 doses (11.0%) – comparatively those who 
had one and two doses of vaccine had significantly lower prevalence(s) of HPV 16/18: 23.7% 
(95% CI 18.1, 30.5) and 21.0% (95% CI 16.8, 26.0) respectively when compared to those who 
had 0 doses.  Prevalence of HPV 31/33/45 was no different in women who received 0 or 1 
dose of vaccine: 12.9% (95% CI 11.9, 14.1) and 14.7% (95% CI 10.2, 20.7) respectively but was 
lower in those who received 2 and 3 doses: 8% (95% CI 5.4, 11.6) and 6.2% (95% CI 5.2, 7.4) 
respectively. 
 The univariate analysis showed the odds of infection with HPV 16/18 in women vaccinated 
with 1, 2 and 3 doses (compared to 0 doses) were 0.75 (0.52, 1.06) 0.64 (95% CI 0.48, 0.85) 
and 0.30 (95% CI 0.25, 0.35), respectively.  Comparative odds for HPV 31/33/45 infection were 
1.16 (95% CI 0.74, 1.75), 0.59 (95% CI 0.37, 0.88), and 0.45 (95% CI 0.36, 0.55). 
 
 
Vaccine effectiveness in women with < 3 doses of vaccine 
Table 3 presents VE for prevalent infection with HPV 16/18 and HPV 31/33/45, adjusted for 
age at first vaccination and SIMD.    VE for prevalent HPV 16/18 infection associated with 1, 2 
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and 3 doses was 48.2% (95% CI 16.8-68.9), 54.8% (95% CI 30.7-70.8) and 72.8% (95% CI 62.8-
80.3). Equivalent VE for prevalent 31/33/45 infection associated with 1, 2 and 3 vaccine doses 
was -1.62% (95% CI -85.1 – 45.3), 48.3 % (95% CI 7.6 -71.8) and 55.2 % (95% CI 32.6-70.2). 
Thus, we observed an impact of 1 dose on the prevalence of vaccine-type infection.  
Furthermore, cross-protection for HPV 31/33/45 with 2 doses was similar to that conferred 
by 3 doses even though the 2 doses were largely administered at 0 and 1 months (compared 
with 3 dose schedule of 0, 1 and 6 months). 
 
 
DISCUSSION 
Through the assessment of HPV infection in women immunised via a national catch-up 
programme, we observed an impact of 1 and 2 doses of vaccine on the prevalence of HPV 
16/18 infection – albeit lower than that associated with 3 doses.  Notably, cross protection for 
HPV 31/33/45 with 2 doses was similar to that conferred by 3 doses even though the 2 doses 
were largely administered at 0 and 1 months. Vaccination with 1 dose did not confer a cross 
protective effect against HPV 31/33/45.    
There are caveats to our analysis; as immunisation uptake for the complete schedule has been 
consistently high in Scotland, relatively few women had < 3 doses 
(http://www.isdscotland.org/Health-Topics/Child-Health/publications/index.asp.)  
Consequently,  rare outcomes such as mono infection with HPV 31, 33 and 45 are challenging 
to measure with current numbers.   Furthermore, we did not have knowledge of HPV status 
prior to vaccination and outcomes could not be measured as incident or persistent infection.  
This is apposite considering that analysis was based on women vaccinated as part of a catch-
up programme, so a proportion will have been exposed to HPV, pre-vaccination.  In a previous 
HPV prevalence study in Scotland undertaken prior to the national vaccination programme, 
which utilised urine,  12.6 % of women aged 15-18 were HR-HPV positive (O’ Leary et al 2011).   
Consequently, the VE  described above is likely to be an underestimate of that expected in 
HPV-naïve women.  In addition we also compared older unvaccinated women with younger 
vaccinated women, who may have different attitudes and behaviours with respect to health 
care/screening. In a recent observational study by Palmer et al (2016), uptake of first invitation 
to cervical screening by vaccine status was assessed; immunised women in the catch-up 
cohorts showed higher attendence than unimmunised women, but this may be a result of a 
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greater awareness of health issues and may not be replicated in routinely immunised women. 
Finally, it is feasible that a herd effect may have a bearing on what we have attributed to < 3 
doses 
It is of interest that our overarching observations are consistent with those of Kreimer et al, 
in spite of the clear differences between settings.  Notably, the cross-protective data align 
more with those of the PATRICIA trial , rather than the combined analysis, which reported a 
higher 1 dose VE, albeit a non-significant one. This may reflect differences in the individual 
contribution of HPV 31, 33 and 45 across settings, between-study HPV assay differences or, as 
indicated earlier, it may simply be an issue of power for this low-frequency outcome.   
While an impact of 1 dose was observed, it was lower than that observed with 3 doses. As the 
bulk of 2 dose data was associated with 0 and 1 month scheduling, we cannot compare 1 dose 
effectiveness with data that mimic the “extended” 2 dose schedules which  is current policy 
in Scotland and other settings.  Nevertheless, the lower effectiveness of 1 dose, may  be as a 
consequence of lower immunogenicity.  In a recent study by La Montagne et al (2015) of 376 
Ugandan girls aged between 10 and 11 who received 1,  2 and 3 doses of the bivalent vaccine 
, geometric mean antibody levels (GMTs)  measured at 24 months for HPV 16/18 were inferior 
in women who received 1 dose compared to 3 doses. However, the authors noted that  levels 
were still higher than those observed in adult women who received 1 dose and where efficacy 
(for infection endpoints) had been demonstrated.10   The authors also contended that the 
GMTs associated with one dose were higher than those generated as a consequence of natural 
infection where a partially protective effect had been demonstrated (Safaeian et al 2014). 
While we did/could not measure GMTs in the current analysis, given the average age of 
vaccination was much higher than the Ugandan study, it is tempting to speculate that one 
dose VE will be higher in the routine (12-13 year old) cohorts given their lower likelihood of 
being infected before vaccination and an anticipated higher immunogenic response to the 
vaccine. It will be of interest to see how the VE estimates change when women who were 
vaccinated as part of the routine (12-13 year old) cohort enter the Scottish screening 
programme in late 2015. 
To conclude, while we do not assert that current data on 1 dose protection are sufficient to 
influence policy, given that an impact has been observed in trial settings and in this and other 
population based settings (Brotherton et al 2015) there is now clear evidence to justify 
further, comprehensive assessment of one dose efficacy, given the global implications.  
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Variable Number % Variable 
distribution 
(%) in 
unvaccinate
d 
Variable 
distribution (%) 
in 
1 dose 
vaccinated 
Variable 
distributio
n (%) in 
2 dose 
vaccinated 
Variable 
distribution (%) 
in 
3 dose 
vaccinated 
Birth cohort       
1988 838 14.1 23.1 0.6 0.0 0.1 
1989 1178 19.8 32.4 1.1 0.7 0.0 
1990 1253 21.1 28.0 19.8 21.0 7.7 
1991 937 15.8 7.8 28.2 34.3 27.1 
1992 1317 22.1 6.9 37.9 32.7 48.7 
1993 426 7.2 1.8 12.4 11.3 16.5 
       
       
SIMD       
1 1405 23.6 23.7 31.6 31.0 21.6 
2 1256 21.1 21.1 24.9 27.7 19.7 
3 1131 19.0 19.9 19.2 14.3 18.0 
4 1027 17.3 17.1 14.7 13.0 18.5 
5 1130 19.0 18.2 9.6 14.0 22.2 
       
Age at vaccine 
for those 
vaccinated 
  
    
15-16 1016 43.6 - 21.5 23.7 48.9 
17 685 29.4 - 29.9 29.3 29.4 
18 461 19.8 - 24.9 30.0 17.6 
Over 18 168 7.2 - 23.7 17.0 4.0 
Table 1:  Overall demographics of the population stratified by vaccine status 
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Table 2:  Prevalence (unadjusted) of vaccine and cross-reactive HPV types according to 
number of vaccine doses  
 
 
 
 
Table 3:  Vaccine effectiveness of 1, 2 and 3 doses unadjusted and also adjusted for age at first 
vaccination, birth cohort and Scottish Index of Multiple Deprivation.  
 
No. of 
Doses 
No. of 
samples No. pos 16/18 [%, (95 CI’s)] No. pos 31/33/45 [%, (95 CI’s)] 
0 3619 1062            [ 29.3 (27.9, 30.8)] 468         [ 12.9 (11.9, 14.1)] 
1 177 42                 [ 23.7 (18.1, 30.5)] 26           [14.7 (10.2, 20.7)] 
2 300 63                 [ 21.0 (16.8, 26.0)] 24           [8.0 (5.4, 11.6)] 
3 1853 203                [ 11.0 (9.7, 12.5)] 115        [6.2 (5.2, 7.4)] 
 No. 
of 
Doses 
Unadjusted  
VE  
[%, (95 CI’s)] 
P value Adjusted  
VE:   
[%, (95 CI’s)] 
P value 
HPV 
16/18 0 0 
 
0 
 
 1 25.1 (-5.7,48.0) 0.1093 48.2 (16.8,68.9) 0.0075 
 2 36 (15.3, 52.3) 0.0023 54.8 (30.7, 70.8) <0.0001 
 3 70.2 (65.0, 74.7) <0.0001 72.8 (63.8, 80.3) <0.0001 
HPV  
31/33/45  0 0 
 
0 
- 
 1 -15.9 (-74.6, 25.9) 0.4978 -1.62 (-85.1, 45.3) 0.9588 
 2 41.4 (12.1, 62.8) 0.0143 48.3 (7.6, 71.8) 0.0287 
 3 55.5 (45.1, 64.1) <0.0001 55.2 (32.6, 70.2) <0.0001 
